What Happened
The Supreme Court declined Monday to hear appeals from pharmaceutical companies challenging the Medicare drug-price negotiation program created by the Inflation Reduction Act.
AP says the justices did not comment and left in place federal appeals court rulings dismissing the manufacturers' claims. Reuters says the appeals came from companies including Novo Nordisk, AstraZeneca, Janssen, Bristol Myers Squibb, Novartis and Boehringer Ingelheim.
The program requires the federal government to negotiate prices for certain high-cost Medicare drugs. Reuters reported that the first negotiated prices on 10 drugs went into effect this year, and AP said the government has so far negotiated prices for 25 drugs, including Ozempic, Rybelsus and Wegovy.
Why This Matters
Americans pay more for pharmaceuticals than people in any other nation, Reuters noted. Medicare is one of the biggest buyers in the system, and the legal fight was partly about whether the government can use that buying power directly instead of politely accepting sticker shock in bulk.
The politics are also strange in a very Washington way. The negotiation program came from Biden's signature 2022 law, which no Republican voted for. But AP and Reuters both report the Trump administration has embraced the authority and defended the program as part of its drug-cost agenda.
The Dumb Part With The Word Negotiation
The drugmakers argued this is not real negotiation because the government can impose consequences if they refuse to play. That argument is not nonsense on its face; government power is government power, and courts should take forced participation claims seriously.
But as public messaging, "the federal buyer should not be allowed to bargain over expensive medicine for seniors" lands with the soft grace of a filing cabinet falling down stairs. Ordinary people negotiate over cars, salaries, medical bills, rent, used lawn equipment and suspicious hotel charges. Medicare saying "how about less?" is not exactly a moon landing.
The absurdity is that the same market system that celebrates leverage suddenly gets faint when the leverage belongs to the public program holding the invoice.
The Bottom Line
The Supreme Court did not decide the merits in a full opinion. It simply declined to take these appeals, which means the lower-court rulings against the companies remain in place for now.
So Medicare keeps haggling, drug companies keep complaining, and seniors remain trapped in the great American tradition of needing a legal update before finding out whether medicine might become slightly less financially ridiculous.
Sources
AP: Supreme Court rejects appeals over Medicare price negotiations
Reuters: US Supreme Court rebuffs pharma challenge to Biden-era drug price plan